Publikationen

Journal Impact Factors and Publication guidelines

	Journal Impact Factors 2008-09.pdf[38.58 KB]
	Guideline for publication and presentation.pdf[151.68 KB]

Aktuelle Publikationen

	Thalmann_­2013_­BJUInt_­STAMPEDE_­Mai11.pdf[10.28 KB]
Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Ritchie AW, Russell JM, Thalmann G, Parmar MK, James ND Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int. 2013 May;111(5):697-9. doi: 10.1111/bju.12087.
	Bargetzi_­2013_­JCO_­HD10-HD11_­April20.pdf[84.63 KB]
Boris Böll, Michael Fuchs, Dennis A. Eichenauer, Bastian von Tresckow, Achim Rothe, Andreas Engert, and Peter Borchmann, University Hospital Cologne; Boris Böll, Helen Goergen, Michael Fuchs, Annette Pluetschow, Hans T. Eich, Dennis A. Eichenauer, Bastian von Tresckow, Achim Rothe, Volker Diehl, Andreas Engert, and Peter Borchmann, German Hodgkin Study Group, Cologne; Hans T. Eich, University Hospital Muenster, Muenster; Eckhart Weidmann, Nordwest Hospital Frankfurt, Frankfurt; Christian Junghanß, University Hospital Rostock, Rostock; Alexander Scherpe, Dr. Hancken Clinic, Stade; Oliver Schmalz, Helios Hospital Wuppertal, Wuppertal, Germany; Mario Bargetzi, University Hospital Internal Medicine, Kantonsspital Aarau, Aarau, Switzerland; and Richard Greil, Paracelsus Medical University Salzburg, Salzburg, Austria ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials JCO Apr 20, 2013:1522-1529; DOI:10.1200/JCO.2012.45.4181.
	Hitz_­2013_­AnnHematol_­SAKK38-08_­April17.pdf[74.23 KB]
Hitz F, Fischer N, Pabst T, Caspar C, Berthod G, Eckhardt K, Berardi Vilei S, Zucca E, Mey U Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol. 2013 Apr 17. [Epub ahead of print]
	Fenaux_­2013_­AmJHematol_­APL_­April06.pdf[16.92 KB]
Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, Thomas X, Quesnel B, Cassinat B, Chomienne C, Dombret H, Degos L, Fenaux P; European APL group. Long term follow up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and daunorubincin in the treatment of non elderly APL patients.Am J Hematol. 2013 Apr 6. doi: 10.1002/ajh.23451. [Epub ahead of print]
	Templeton_­2013_­EurUrol_­SAKK08-08_­April06.pdf[84.88 KB]
Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08). Eur Urol. 2013 Apr 6. pii: S0302-2838(13)00294-7. doi: 10.1016/j.eururo.2013.03.040.
	Passweg_­2013_­LeukLymp_­SAKK30-07_­April02.pdf[12.63 KB]
Passweg JR, Pabst T, Blum S, Bargetzi M, Li Q, Heim D, Stussi G, Gregor M, Leoncini L, Meyer-Monard S, Brauchli P, Chalandon Y; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Azacytidine for acute myeloid leukemia in elderly or frail patients: A phase II trial (SAKK 30/07). Leuk Lymphoma. 2013 Apr 2. [Epub ahead of print]
	Dietrich_­2013_­BMC_­BreastCancer_­Maerz25.pdf[11.73 KB]
Templeton AJ, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer. 2013 Mar 25;13:153. doi: 10.1186/1471-2407-13-153.
	Thalmann_­2013_­ClinOncol_­STAMPEDE_­Maerz8.pdf[10.34 KB]
Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Ritchie AW, Russell JM, Thalmann G, Parmar MK, James ND.Prostate Radiotherapy for Men with Metastatic Disease: A New Comparison in the STAMPEDE Trial. Clin Oncol (R Coll Radiol). 2013 Mar 8. [Epub ahead of print]
	Oakman_­2013_­AnnOncol_­BIG02-98_­Jan4.pdf[70.61 KB]
Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the Breast International Group 02-98 phase III trial Ann Oncol. 2013 Jan 4
	Mathers_­2012_­Lancet_­CAPP_­Dec13.pdf[17.63 KB]
Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard ML, Dunlop M, Ho JW, Hodgson S, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen H, Gerdes AM, Barker G, Crawford G, Elliott F, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Bishop DT, Burn J; on behalf of the CAPP2 Investigators. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol. 2012 Dec;13(12):1242-1249. doi: 10.1016/S1470-2045(12)70475-8
	Azim_­2012_­JCO_­IBCSG_­Nov19.pdf[263.09 KB]
Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2012 Nov 19
	Behringer_­2012_­JCO_­HD13-15_­Nov13.pdf[77.75 KB]
Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P. Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials J Clin Oncol. 2012 Nov 13
	Ewertz_­2012_­JCO_­BIG1-98_­Nov10.pdf[77.47 KB]
Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial J Clin Oncol. 2012 Nov 10;30(32):3967-75. doi: 10.1200/JCO.2011.40.8666
	Helbling_­2012_­AnnOncol_­SAKK4107_­Nov8.pdf[219.42 KB]
Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Gloor B, Burkhard R, Winterhalder R, Madlung A, Rauch D, Saletti P, Widmer L, Borner M, Baertschi D, Yan P, Benhattar J, Leibundgut EO, Bougel S, Koeberle D. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07 Ann Oncol. 2012 Nov 8
	Coates_­2012_­IBCSGVIII-IX_­BreastCanRe_­Nov5.pdf[364.59 KB]
Coates AS, Millar EK, O'Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M, Gusterson B, Musgrove EA, Sutherland RL. Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res. 2012 Nov 5
	Gautschi_­2012_­LungCancer_­SAKK1905_­Oct31.pdf[7.06 KB]
Gautschi O, Dingemans AM, Crowe S, Peters S, Roder H, Grigorieva J, Roder J, Zappa F, Pless M, Brutsche M, Baty F , Bubendorf L, Hsu Schmitz SF, Na KJ, Carbone D, Stahel R, Smit E. VeriStrat(®) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528 Lung Cancer. 2012 Oct 31
	Roth_­2012_­JNatlCanInst_­SAKK6000_­Oct25.pdf[12.61 KB]
Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, Nordlinger B, Bosman F, Van Cutsem E. Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer J Natl Cancer Inst. 2012 Nov 7;104(21):1635-46. doi: 10.1093/jnci/djs427
	Ossenkoppele_­2012_­Blood_­HOVON81_­Oct9.pdf[18.06 KB]
Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems DM, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerdt O, Wijermans P, Passweg JR, Lowenberg B. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase II trial of HOVON/SAKK Blood. 2012 Oct 9
	Bernhard_­2012_­AnnOncol_­IBCSG3303_­Sep27.pdf[96.06 KB]
Bernhard J, Aldridge J, Butow PN, Zoller P, Brown R, Smith A, Juraskova I. Patient-doctor agreement on recall of clinical trial discussion across cultures. Ann Oncol. 2012 Sep 27
	Blum_­2012_­BMC_­SAKK9506_­Sep24.pdf[10.77 KB]
Blum D, Koeberle D, Ribi K, Hsu Schmitz SF, Uitger U, Klingbiel D, Strasser F. Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. BMC Palliat Care. 2012 Sep 24;11(1):19
	Gröschel_­2012_­JCO_­HOVON42_­Sep24.pdf[165.6 KB]
Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R. Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol. 2012 Sep 24
	Eggermont_­2012_­JCO_­EORTC18991_­Sep24.pdf[79.19 KB]
Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U. Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. J Clin Oncol. 2012 Sep 24
	Zappa_­2012_­LungCan_­SAKK1905_­Sep22.pdf[16.77 KB]
Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, Brauchli P, Ribi K, Pless M; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) Lung Cancer. 2012 Sep 22. doi: 10.1016/j.lungcan.2012.08.017
	Sydes_­2012_­Trials_­STAMPEDE_­Sep15.pdf[15.1 KB]
Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, de Bono JS, Dearnaley DP, Dwyer J, Green C, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann G, James ND. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012 Sep 15;13(1):168
	Cathomas_­2012_­ClinCan_­SAKK0807_­Sep12.pdf[76.09 KB]
Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07) Clin Cancer Res. 2012 Sep 12
	Tanguy-Schmidt_­2012_­BioBlood_­GRAALL03_­Sep5.pdf[90.15 KB]
Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, Escoffre M, Huguet F, Réa D, Delannoy A, Cahn JY, Vernant JP, Ifrah N, Dombret H, Thomas X. Long-Term Follow-up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study. Biol Blood Marrow Transplant. 2012 Sep 6. pii: S1083-8791(12)00355-2. doi: 10.1016/j.bbmt.2012.08.021
	Karlsson_­2012_­AnnOncol_­IBCSG_­Jul9.pdf[76.14 KB]
Karlsson P, Cole BF, Chua BH, Price KN, Lindtner J, Collins JP, Kovács A, Thürlimann B, Crivellari D, Castiglione-Gertsch M, Forbes JF, Gelber RD, Goldhirsch A, Gruber G; for the International Breast Cancer Study Group. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol. 2012 Jul 9
	Sasse_­2012_­AnnOncol_­GHSG_­Jul5.pdf[14.47 KB]
Sasse S, Klimm B, Görgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, Koch O, Wilhelm M, Trenn G, Finke J, Müller RP, Diehl V, Eich HT, Borchmann P, Engert A; German Hodgkin Study Group (GHSG). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol. 2012 Jul 5
	Delapasqua_­2012_­IBCSGVIII_­Breast_­Jun29.pdf[370.53 KB]
Dellapasqua S, Bagnardi V, Regan MM, Rotmensz N, Mastropasqua MG, Viale G, Maiorano E, Price KN, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Colleoni M. A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. Breast. 2012 Oct;21(5):621-8
	Oppliger_­2012_­LeukRes_­CLL_­Jun25.pdf[10.19 KB]
Oppliger Leibundgut E, Rogenmoser-Dissler D, de Beer D, Porret NA, Zibellini S, Dürig J, Röth A, Klingbiel D, Baerlocher GM. CLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasms. Leuk Res. 2012 Sep;36(9):1204-7
	Ghadjar_­2012_­Radio_­and_­Oncol_­SAKK1094_­Jun20.pdf[427.08 KB]
Ghadjar P, Simcock M, Zimmermann F, Betz M, Bodis S, Bernier J, Studer G, Aebersold DM; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiother Oncol. 2012 Jun 20
	Mamot_­2012_­JDrugTarget_­Consult_­Jun20.pdf[10.18 KB]
Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J Drug Target. 2012 Jun;20(5):422-32
	Huober_­2012_­AnnOncol_­IBCSG_­Jun14.pdf[152.61 KB]
Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Oehlschlegel C, Price KN, Gelber RD3, Regan MM, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials AnnOncol. 2012 June 14
	Cornelissen_­2012_­JCO_­HOVON_­Jun10.pdf[153.45 KB]
Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, Beverloo HB, van Marwijk Kooy M, Wijermans PW, Biemond BJ, Vellenga E, Verdonck LF, Ossenkoppele GJ, Löwenberg B. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol. 2012 Jun 10;30(17):2140-6.
	Avet-Loiseau_­2012_­IFM99_­Jun1.pdf[124.32 KB]
Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P. Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. J Clin Oncol. 2012 Jun 1;30(16):1949-52.
	Ejlertsen_­2012_­AnnOncol_­BIG1-98_­May23.pdf[78.23 KB]
Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Müller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H; Danish Breast Cancer Cooperative Group; BIG 1-98 Collaborative Group; International Breast Cancer Study Group Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial Ann Oncol. 2012 May;23(5):1138-44
	Früh_­2012_­ClinLungCan_­SAKK1508_­May23.pdf[13.92 KB]
Früh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M; Swiss Group for Clinical Cancer Research. Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08). Clin Lung Cancer. 2012 May 23.
	Schraml_­2012_­OncolRep_­SAKK5007_­May18.pdf[11.88 KB]
Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi M, Moch H, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep. 2012 May 18. doi: 10.3892/or.2012.1826
	James_­2012_­Lancet_­STAMPEDE_­May13.pdf[34 KB]
James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK; STAMPEDE investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 2012 May;13(5):549-58
	Attal_­2012_­NEJM_­IFM05-02_­May10.pdf[128.63 KB]
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1782-91
	Garderet_­2012_­JCO_­IFM05-04_­May9 .pdf[162.03 KB]
Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 May 14
	Ribi_­2012_­BrJCancer_­BIG-98_­May8.pdf[14.35 KB]
Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer. 2012 May 8;106(10):1618-25. doi: 10.1038/bjc.2012.156.
	Schoenewolf_­2012_­CaseRepOnco_­SAKK5007_­May5.pdf[13.24 KB]
Schoenewolf NL, Dummer R, Mihic-Probst D, Moch H, Simcock M, Ochsenbein A, Gillessen S, Schraml P, von Moos R; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Rep Oncol. 2012 May;5(2):280-289
	Fernandez-Cuesta_­2012_­BIG02-98_­May2.pdf[347.22 KB]
Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res. 2012 May 2;14(3):R70
	Engert_­2012_­Lancet_­HD15_­Apr3.pdf[25.58 KB]
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, and the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 Apr 3
	Bally_­2012_­JCO_­APL93_­Apr2.pdf[80.26 KB]
Bally C, Fadlallah J, Leverger G, Bertrand Y, Robert A, Baruchel A, Guerci A, Recher C, Raffoux E, Thomas X, Leblanc T, Idres N, Cassinat B, Vey N, Chomienne C, Dombret H, Sanz M, Fenaux P, Adès L. Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group JCO. 2012 Apr 2
	Rossi_­2012_­JCO_­COCIS_­Apr2.pdf[181 KB]
Antonio Rossi, Massimo Di Maio, Paolo Chiodini, Robin Michael Rudd, Hiroaki Okamoto, Dimosthenis Vasilios Skarlos, Martin Fru¨h, Wendi Qian, Tomohide Tamura, Epaminondas Samantas, Taro Shibata, Francesco Perrone, Ciro Gallo, Cesare Gridelli, Olga Martelli, and Siow-Ming Lee. Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. JCO April 2
	Hanfstein_­2012_­Leuk_­CMLIV_­Mar26.pdf[21.2 KB]
Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012 Mar 26. doi: 10.1038/leu.2012.85
	Regan_­2012_­JNatlCan_­BIG1-98_­Mar21.pdf[30.91 KB]
Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial J Natl Cancer Inst. 2012 Mar 21;104(6):441-51
	Pabst_­2012_­Blood_­HOVON_­Mar15.pdf[14.78 KB]
Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Löwenberg B. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose-escalation of cytarabine Blood. 2012 Mar 15
	Brown_­2012_­JCO_­IBCSG33-03_­Mar10.pdf[10.23 KB]
Brown R, Butow P, Wilson-Genderson M, Bernhard J, Ribi K, Juraskova I. Meeting the decision-making preferences of patients with breast cancer in oncology consultations: impact on decision-related outcomes. J Clin Oncol. 2012 Mar 10;30(8):857-62
	Cuccuini_­2012_­Blood_­BIOCoral_­Mar9.pdf[13 KB]
Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C, Cogliatti S, Hirchaud E, Ysebaert L, Bron D, Soulier J, Gaulard P, Houlgatte R, Gisselbrecht C, Thieblemont C. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by HDT/ASCT. A bio-CORAL report Blood. 2012 Mar 9
	Faris_­2012_­JCO_­SAKK6000_­Mar5.pdf[57.77 KB]
Jason E. Faris and David P. Ryan, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA. Trees, Forests, and Other Implications of a BRAF Mutant Gene Signature in Patients With BRAF Wild-Type Disease J Clin Oncol. 2012 Mar 5
	Popovici_­2012_­JCO_­SAKK6000_­Mar5_­abs.pdf[12.21 KB]
Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, Van Cutsem E, Xie T, Bosman FT, Roth AD, Delorenzi M. Identification of a Poor-Prognosis BRAF-Mutant-Like Population of Patients With Colon Cancer J Clin Oncol. 2012 Mar 5
	Baselga_­2012_­Lancet_­IBCSG-NeoALLTO_­Feb18.pdf[34.48 KB]
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40
	Pesce_­2012_­EJC_­SAKK7003_­Feb.pdf[432.61 KB]
Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03) Eur J Cancer. 2012 Feb;48(3):377-84
	Renner_­2012_­Haemato_­SAKK3606_­Feb7.pdf[77.09 KB]
Renner C, Zinzani P, Gressin R, Klingbiel D, Dietrich PY, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N. A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 2012 Feb 7
	Ghadjar_­2012_­IntJRaOncol_­SAKK1094_­Feb1.pdf[13.46 KB]
Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, Töpfer M, Zimmermann F, Betz M, Glanzmann C, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK) Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):524-31
	VonTresckow_­2012_­JClin_­HD14_­Jan23.pdf[92.29 KB]
von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial J Clin Oncol. 2012 Jan 23.
	Hegi_­2012_­Acta_­EORTC_­Jan15.pdf[91.17 KB]
Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial Acta Neuropathol. 2012 Jan 15.
	Sydes_­2011_­Trials_­STAMPEDE_­Dec13.pdf[11.53 KB]
Sydes MR, James ND, Mason MD, Clarke NW, Amos C, Anderson J, de Bono J, Dearnaley DP, Dwyer J, Jovic G, Ritchie A, Russell M, Sanders K, Thalmann G, Parmar MK. Flexible trial design in practice - dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. Trials. 2011 Dec 13;12 Suppl 1:A3
	Kiefer_­2011_­AnnOncol_­OSHO-53_­Nov24.pdf[15.69 KB]
Kiefer T, Hirt C, Späth C, Schüler F, Al-Ali HK, Wolf HH, Herbst R, Maschmeyer G, Helke K, Kessler C, Niederwieser D, Busemann C, Schroeder H, Vogelgesang S, Kirsch M, Montemurro M, Krüger WH, Dölken G; for the Ostdeutsche Studiengruppe Hämatologie und Onkologie. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. Ann Oncol. 2011 Nov 24. [Epub ahead of print]
	Darby_­2011_­Lancet_­EBCTCG_­Nov12.pdf[45.59 KB]
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707-16
	Eggermont_­2011_­EORTC_­EurJCancer_­Nov4.pdf[129.26 KB]
Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2011 Nov 4. [Epub ahead of print]
	Fabarius_­2011_­Blood_­CMLIV_­Oct28.pdf[97.23 KB]
Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R. Impact of ACA at diagnosis on prognosis of CML: long-term observation from 1151 patients of the randomized CML Study IV. Blood. 2011 Oct 28. [Epub ahead of print]
	Matter_­2011_­ValueH_­Oct22.pdf[149.95 KB]
Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health Epub 2011 Oct 22.
	Viale_­2011_­AnnOncol_­BIG1-98_­Oct22.pdf[131.12 KB]
Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol. 2011 Oct;22(10):2201-7
	Vidal_­2011_­NatlCanInst_­SAKK35-98_­Oct21.pdf[88.17 KB]
Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, Pettengell R, Witzens-Harig M, Shpilberg O. Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. J Natl Cancer Inst. 2011 Oct 21. [Epub ahead of print]
	Regan_­2011_­Lancet_­BIG1-98_­Oct20.pdf[58.95 KB]
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; for the members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (IBCSG) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8•1 years median follow-up. Lancet Oncol. 2011 Nov;12(12):1101-1108
	Zaman_­2011_­AnnOncol_­SAKK21-07_­Oct14.pdf[90 KB]
Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S; on behalf of the Swiss Group for Clinical Cancer Research (SAKK) Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) Ann Oncol. 2011 Oct 14. [Epub ahead of print]
	Pfreundschuh_­2011_­Lancet_­MInt_­Oct12.pdf[20.7 KB]
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; for the MabThera International Trial (MInT) Group.CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-1022
	Borchmann_­2011_­JClinOncol_­HD12_­Oct11.pdf[94.94 KB]
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Oct 11. [Epub ahead of print]
	Hitz_­2011_­AnnHematol_­Sep29.pdf[867.59 KB]
Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. Ann Hematol. 2011 Sep 29. [Epub ahead of print]
	Vellenga_­2011_­Blood_­HOVON_­Sep27.pdf[11.63 KB]
Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF, Löwenberg B. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011 Sep 27. [Epub ahead of print]
	Thieblemont_­2011_­JClinOncol_­Sep26.pdf[17.25 KB]
Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C. The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. J Clin Oncol. 2011 Nov 1;29(31):4079-87
	Chirgwin_­2011_­BreastCancerResTreat_­BIG1-98_­Sep4.pdf[65.58 KB]
Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat. 2011 Sep 4. [Epub ahead of print]
	Davies_­2011_­Lancet_­EBCTCG_­Jul28.pdf[45.72 KB]
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011 Aug 27;378(9793):771-84. Epub 2011 Jul 28.
	Bonnefoi_­2011_­LancetOncol_­EORTC10994_­May11.pdf[22.61 KB]
Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol. 2011 Jun;12(6):527-39. Epub 2011 May 11.
	vonMoos_­2011_­AnnOncol_­SAKK50-07_­Apr28.pdf[13.23 KB]
von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol. 2011 Apr 28. [Epub ahead of print]
	Hehlmann_­2011_­JClinOncol_­CMLIV_­Mar21.pdf[119.64 KB]
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011 Apr 20;29(12):1634-42. Epub 2011 Mar 21.
	Loewenberg_­2011_­HOVON-SAKKAML42_­NEnglJMed_­Mar17.pdf[16.39 KB]
Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011 Mar 17;364(11):1027-36.
	Ghadjar_­2011_­IntJRadiatOncolBiolPhys_­SAKK10-94_­Feb16.pdf[13.12 KB]
Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, Töpfer M, Zimmermann F, Betz M, Glanzmann C, Aebersold DM; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-up of a Randomized Phase III Trial (SAKK 10/94). Int J Radiat Oncol Biol Phys. 2011 Feb 16. [Epub ahead of print]
	Colleoni_­2011_­JClinOncol_­BIG1-98_­Feb14.pdf[15.18 KB]
Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study. J Clin Oncol. 2011 Feb 28. [Epub ahead of print]
	Koeberle_­2011_­EndocrRelatCancer_­SAKK23-03_­Feb11.pdf[64.16 KB]
Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B. Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with ER-positive, HER-2 positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer. 2011 Feb 11. [Epub ahead of print]
	Madlung_­2011_­Cancer_­noabstract_­Feb1.pdf[9.78 KB]
Madlung A, Simcock M, Ghadjar P. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2011 Feb 1. doi: 10.1002/cncr.25949. [Epub ahead of print]
	Aebi_­2011_­AnnOncol_­IBCSGTrial-IX_­Jan31.pdf[66.19 KB]
Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Ann Oncol. 2011 Jan 31. [Epub ahead of print]
	Passweg_­2011_­JClinOncol_­SAKK33-99_­Jan20.pdf[69.15 KB]
Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011 Jan 20;29(3):303-9. Epub 2010 Dec 13.
	Stupp_­2011_­JClinOncol_­noabstract_­Jan4.pdf[9.73 KB]
Stupp R, Betticher D, Ris HB, Peters S, Pless M. Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer: A Curative Approach. J Clin Oncol. 2011 Jan 4. [Epub ahead of print]
	Ruhstaller_­2011_­JClinOncol_­SAKK75-06_­Jan4.pdf[14.48 KB]
Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V. Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06). J Clin Oncol. 2011 Jan 4. [Epub ahead of print]
	Correa_­2010_­NatlCancerInstMonogr.pdf[65.05 KB]
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162-77.
	Gallerani_­2010_­ActaOncol_­SAKK-Sendo_­Dec27.pdf[11.81 KB]
Gallerani E, Bauer J, Hess D, Boehm S, Droege C, Jeckelmann S, Miani M, Herrmann R, Marsoni S, Sperka S, Sessa C. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies. Acta Oncol. 2010 Dec 27. [Epub ahead of print]
	Passweg_­2010_­JClinOncol_­SAKK33-99_­Dec13.pdf[69.74 KB]
Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A. Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care--SAKK 33/99. J Clin Oncol. 2011 Jan 20;29(3):303-9. Epub 2010 Dec 13.
	Michallet_­2010_­Blood_­Nov24.pdf[16.38 KB]
Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D; EBMT Chronic Leukemia Working Party. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011 Feb 3;117(5):1516-21. Epub 2010 Nov 24.
	Moreau_­2010_­Blood_­IFM2005-01_­Nov23.pdf[11.48 KB]
Moreau P, Attal M, Pégourié B, Planche L, Hulin C, Facon T, Stoppa AM, Fuzibet JG, Grosbois B, Doyen C, Ketterer N, Sebban C, Kolb B, Chaleteix C, Dib M, Voillat L, Fontan J, Garderet L, Jaubert J, Mathiot C, Esseltine D, Avet-Loiseau H, Harousseau JL. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2010 Nov 23. [Epub ahead of print]
	Phillips_­2010_­BreastCancerResTreat_­BIG1-98_­Nov3.pdf[11.8 KB]
Phillips KA, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2010 Nov 3. [Epub ahead of print]
	Bernhard_­2010_­BrJCancer_­abstract_­Sep28.pdf[14.53 KB]
Bernhard J, Dietrich D, Glimelius B, Hess V, Bodoky G, Scheithauer W, Herrmann R. Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer. 2010 Sep 28. [Epub ahead of print]
	Wuethrich_­2010_­Anesthesiology_­Sep10.pdf[15.78 KB]
Wuethrich PY, Hsu Schmitz SF, Kessler TM, Thalmann GN, Studer UE, Stueber F, Burkhard FC. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: a retrospective study. Anesthesiology. 2010 Sep;113(3):570-6.
	Joerger_­2010_­AnnOncol_­Outcomes_­Sep13.pdf[15.09 KB]
Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M.Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.Ann Oncol. 2010 Sep 13. [Epub ahead of print]
	Harousseau_­2010_­JClinOncol_­IFM2005-01_­Sep7.pdf[17.57 KB]
Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P.Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial.J Clin Oncol. 2010 Sep 7. [Epub ahead of print]
	Brauchli_­2010_­JClinOncol_­noabstract_­Aug30.pdf[10.17 KB]
Brauchli P, Thürlimann B, Crowe SN, Herrmann R.What Is the Value of the 21-Gene Recurrence Score?J Clin Oncol. 2010 Aug 30. [Epub ahead of print]
	Ott_­2010_­Blood_­Ricover-60_­Aug24.pdf[12.64 KB]
Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, Thorns C, Feller AC, Lenze D, Hummel M, Stein H, Müller-Hermelink HK, Frank M, Hansmann ML, Barth TF, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Loeffler M, Rosenwald A.Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.Blood. 2010 Aug 24. [Epub ahead of print]
	Eich_­2010_­JClinOncol_­HD11_­Aug16.pdf[16.42 KB]
Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial.J Clin Oncol. 2010 Sep 20;28(27):4199-206. Epub 2010 Aug 16.
	Engert_­2010_­NEnglJMed_­HD-10_­Aug12.pdf[16.14 KB]
Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52.
	Martinelli_­2010_­JClinOncol_­SAKK35-98_­Aug9.pdf[16.45 KB]
Martinelli G, Hsu Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, Okkinga E, Stupp R, Stahel R, Heizmann M, Vorobiof D, Lohri A, Dietrich PY, Zucca E, Ghielmini M.Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98.J Clin Oncol. 2010 Aug 9. [Epub ahead of print]
	Lugthart_­2010_­JClinOncol_­HOVON_­July26.pdf[10.77 KB]
Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Ossenkoppele GJ, Vellenga E, Eva VD, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H.Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia.J Clin Oncol. 2010 Aug 9. [Epub ahead of print]
	Behringer_­2012_­AnnOncol_­HD14_­Jul23.pdf[77.76 KB]
Behringer K, Thielen I, Mueller H, Goergen H, Eibl AD, Rosenbrock J, Halbsguth T, Eichenauer DA, Fuchs M, Reiners KS, Renno JH, van der Ven K, Kuehr M, von Wolff M, Diehl V, Engert A, Borchmann P. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial Ann Oncol. 2012 Jul;23(7):1818-25. doi: 10.1093/annonc/mdr575
	Rochlitz_­2010_­AnnOncol_­SAKK24-06_­Juli1.pdf[12 KB]
Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol. 2010 Jul 1. [Epub ahead of print]
	Jost_­2010_­GastrointestEndosc_­SAKK75-02_­June.pdf[13.18 KB]
Jost C, Binek J, Schuller JC, Bauerfeind P, Metzger U, Werth B, Knuchel J, Frossard JL, Bertschinger P, Brauchli P, Meyenberger C, Ruhstaller T. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointest Endosc. 2010 Jun;71(7):1114-1121. Epub 2010 Mar 20.
	Ladenstein_­2010_­JClinOncol_­Euro-EWING-99.June14.pdf[12.42 KB]
Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jürgens H. Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J Clin Oncol. 2010 Jun 14. [Epub ahead of print]
	Moreau_­2010_­Leukemia_­IFM-2005-01_­June.pdf[4.71 KB]
Moreau P, Hulin C, Marit G, Caillot D, Facon T, Lenain P, Berthou C, Pégourié B, Stoppa AM, Casassus P, Michallet M, Benboubker L, Maisonneuve H, Doyen C, Leyvraz S, Mathiot C, Avet-Loiseau H, Attal M, Harousseau JL. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia. 2010 Jun;24(6):1233-5. Epub 2010 Apr 29
	Taphoorn_­2010_­EurJCancer_­EORTC QLQ-BN20.April.pdf[11.52 KB]
Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, Stupp R, Mirimanoff RO, van den Bent MJ, Bottomley A; EORTC Quality of Life Group, and Brain Cancer, NCIC and Radiotherapy Groups. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010 Apr;46(6):1033-40. Epub 2010 Feb 22.
	VonMoos_­2010_­Onkologie_­SAKK41-03_­May14.pdf[6.99 KB]
von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie. 2010;33(6):295-9. Epub 2010 May 14.
	Matter-Walstra_­2010_­AnnOncol_­Outcomes_­May5.pdf[12.76 KB]
Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC.Trastuzumab beyond progression: a cost-utility analysis.Ann Oncol. 2010 May 5. [Epub ahead of print]
	Engert_­2010_­JClinOncol_­HD-15_­May1.pdf[7.7 KB]
Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.J Clin Oncol. 2010 May 1;28(13):2239-45. Epub 2010 Apr 5.
	Phillips_­2010_­Breast_­IBCSG_­Apr10.pdf[13.96 KB]
Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast. 2010 Oct;19(5):388-95. Epub 2010 Apr 10.
	Ruhstaller_­2010_­Onkologie_­sakk76-02_­Apr9.pdf[7.57 KB]
Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Thierstein S, von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02).Onkologie. 2010;33(5):222-8. Epub 2010 Apr 9.
	Lowenberg_­2010_­Blood_­HOVON-43_­April1.pdf[9.89 KB]
Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma MR, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase III study. Blood. 2010 Apr 1;115(13):2586-91. Epub 2010 Jan 26.
	Pagani_­2010_­JNatlCancerInst_­ESO-MBC_­March10.pdf[55.54 KB]
Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F; on behalf of the ESO–MBC Task Force.International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?J Natl Cancer Inst. 2010 Mar 10. [Epub ahead of print]
	Leupin_­2010_­LeukLymphoma_­SAKK34-02_­March10.pdf[58.07 KB]
Leupin N, Schuller JC, Solenthaler M, Heim D, Rovo A, Beretta K, Gregor M, Bargetzi MJ, Brauchli P, Himmelmann A, Hanselmann S, Zenhäusern R. Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02).Leuk Lymphoma. 2010 Mar 10. [Epub ahead of print]
	Koeberle_­2010_­Oncologist_­SAKK77-06_­March4.pdf[60.45 KB]
Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G.Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06).Oncologist. 2010 Mar 4. [Epub ahead of print]
	Barlogie_­2010_­JClinOncol_­IFM90-IFM04-IFM9902-IFM9904_­March1.pdf[56.54 KB]
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19.
	Paridaens_­2010_­BreastCancerResTreat_­IBCSG11-93_­Feb27.pdf[58.9 KB]
Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thürlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A. Adjuvant!((c)) Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2010 Feb 27. [Epub ahead of print]
	Ess_­2010_­CancerEpidemiol_­CancerRegistry_­Feb23.pdf[53.47 KB]
Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, Thürlimann B. Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol. 2010 Feb 23. [Epub ahead of print]
	Antonov_­2010_­BMCCancer_­BIG1-98_­Feb8.pdf[59.92 KB]
Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A, Thurlimann B, Giobbie-Hurder A, Viale G, Altermatt HJ, Aebi S, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer. 2010 Feb 9;10(1):37. [Epub ahead of print]
	Biffi_­2010_­WorldJGastroenterol_­SAKK43-99_­Feb21.pdf[56.11 KB]
Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F, Bonomo G, Crosta C, Huber O. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol. 2010 Feb 21;16(7):868-74.
	Roth_­2010_­JClinOncol_­SAKK60-00_­Jan20.pdf[61.21 KB]
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. J Clin Oncol. 2010 Jan 20;28(3):466-74. Epub 2009 Dec 14.
	Roussel_­2010_­Blood_­IFM-2005 01_­Jan7.pdf[58.19 KB]
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010 Jan 19. [Epub ahead of print]
	Arriagada_­2010_­JClinOncol_­IALT_­abstract_­Jan1.pdf[57.07 KB]
Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42.

Liste der wissenschaftlichen Publikationen

Einschliesslich IBCSG-Studien mit massgeblicher Teilnahme der SAKK.

	SAKK_­Publications_­2012.pdf[152.01 KB]
	SAKK_­Publications_­2011.pdf[170.82 KB]
	SAKK_­Publications_­2010.pdf[61.54 KB]
	SAKK Publications 2009.pdf[118.05 KB]
	SAKK Publications 2008.pdf[42.03 KB]
	SAKK Publications 2007.pdf[24.9 KB]
	SAKK Publications 2006.pdf[30.53 KB]
	SAKK Publications 2005.htm[37.77 KB]
	SAKK Publications 2004.htm[11.12 KB]
	SAKK Publications 2003.htm[10.58 KB]
	SAKK Publications 2002.htm[5.44 KB]
	SAKK Publications 2001.htm[7.92 KB]
	SAKK Publications 2000.htm[7 KB]